922720-13-6

Upstream product

• 922719-96-8 4-(2,3-difluoro-4-methoxy-benzyl)-5-methyl-1H-pyrazol-3-ol 
• 6564-72-3 2,3,4,6-tetra-O-benzyl-D-glucopyranose 
• 922719-78-6 2-(2,3-difluoro-4-methoxy-benzyl)-3-oxo-butyric acid ethyl ester 
• 261763-32-0 2,3-difluoro-1-methoxy-4-methylbenzene 
• 689254-23-7 1-(bromomethyl)-2,3-difluoro-4-methoxybenzene 

Downstream Products

• 922720-65-8 4-(2,3-difluoro-4-methoxy-benzyl)-1-isopropyl-5-methyl-3-(6-O-methoxycarbonyl-β-D-glucopyranos-1-yloxy)-1H-pyrazole 
• 922721-24-2 4-(2,3-difluoro-4-methoxy-benzyl)-1-isopropyl-5-methyl-3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranos-1-yloxy)-1H-pyrazole 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE

The invention relates toa pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the trea

METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES

The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for